157 related articles for article (PubMed ID: 28343172)
1. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
[TBL] [Abstract][Full Text] [Related]
3. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
[TBL] [Abstract][Full Text] [Related]
5. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
[TBL] [Abstract][Full Text] [Related]
7. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis.
Liaskos C; Spyrou V; Athanasiou LV; Orfanidou T; Mavropoulos A; Rigopoulou EI; Amiridis GS; Shoenfeld Y; Billinis C; Bogdanos DP
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):384-90. PubMed ID: 25575461
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
[TBL] [Abstract][Full Text] [Related]
9. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
[TBL] [Abstract][Full Text] [Related]
11. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.
Homsak E; Micetić-Turk D; Bozic B
Wien Klin Wochenschr; 2010 May; 122 Suppl 2():19-25. PubMed ID: 20517666
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
[TBL] [Abstract][Full Text] [Related]
15. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.
Liaskos C; Rigopoulou EI; Orfanidou T; Bogdanos DP; Papandreou CN
Clin Dev Immunol; 2013; 2013():968041. PubMed ID: 23710207
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.
Koutroubakis IE; Drygiannakis D; Karmiris K; Drygiannakis I; Makreas S; Kouroumalis EA
Dig Dis Sci; 2005 Dec; 50(12):2330-4. PubMed ID: 16416183
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.
Lakatos PL; Altorjay I; Szamosi T; Palatka K; Vitalis Z; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Barta Z; Stocker W; Papp J; Veres G; Papp M;
Inflamm Bowel Dis; 2009 Mar; 15(3):365-74. PubMed ID: 18972554
[TBL] [Abstract][Full Text] [Related]
19. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein 2 antibodies in Crohn's disease.
Roggenbuck D; Reinhold D; Werner L; Schierack P; Bogdanos DP; Conrad K
Adv Clin Chem; 2013; 60():187-208. PubMed ID: 23724745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
